ReviewHepatobiliary surgery and nutrition2020
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.
Review in Hepatobiliary surgery and nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 86 citations in OpenAlex.
- Metformin in skin diseases: the role of gut microbiota and immune response.Pharmacological reports : PR · 2026Review
- Bile Acid Binding Resins Improve Glucagon Receptor Agonist-Mediated Weight Loss in Diet-Induced Obese Mice.Obesity (Silver Spring, Md.) · 2026Article
- Bile acids in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Key Transcription Factors: Avenue for Treating Alcoholic Liver Disease.Current medical science · 2025Review
- Ileal FXR Knockdown Ameliorates MASLD Progression in Rats via Modulating Bile Acid Metabolism Mediated by Gut Microbiota.Journal of gastroenterology and hepatology · 2025Article
- Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease.Frontiers in immunology · 2025Review
- A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Gut Microbiota as Emerging Players in the Development of Alcohol-Related Liver Disease.Biomedicines · 2024Review
- Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Review
- Bile Acid Composition and Transcriptome Analysis of the Liver and Small Intestine in Different Species.Metabolites · 2024Article
- Reversal of hepatic accumulation of nordeoxycholic acid underlines the beneficial effects of cholestyramine on alcohol-associated liver disease in mice.Hepatology communications · 2024Article
- Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.Journal of advanced research · 2024Review
- Microbiota Implications in Endocrine-Related Diseases: From Development to Novel Therapeutic Approaches.Biomedicines · 2024Review
- Editorial: Prebiotics in the management of obesity and associated metabolic disorders.Frontiers in endocrinology · 2024Article
- Article
- Gut liver brain axis in diseases: the implications for therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Hepatic steatosis is associated with dysregulated cholesterol metabolism and altered protein acetylation dynamics in chickens.Journal of animal science and biotechnology · 2023Article
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.Cardiovascular research · 2023Review
- SIRT1 activation synergizes with FXR agonism in hepatoprotectionActa pharmaceutica Sinica. B · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Bile acids are synthesized from cholesterol only in hepatocytes. Bile acids circulating in the enterohepatic system act as physiological detergent molecules to help solubilize biliary cholesterol and emulsify dietary lipids and fat-soluble vitamins in small intestine. Bile acids are signaling molecules that activate nuclear receptor farnesoid X receptor (FXR) and cell surface G protein-coupled receptor TGR5. FXR critically regulates bile acid homeostasis by mediating bile acid feedback inhibition of hepatic bile acid synthesis. In addition, bile acid-activated cellular signaling pathways regulate metabolic homeostasis, immunity, and cell proliferation in various metabolically active organs. In the small and large intestine, gut bacterial enzymes modify primary bile acids to generate secondary bile acids to help shape the bile acid pool composition and subsequent biological effects. In turn, bile acids exhibit anti-microbial properties and modulate gut microbiota to influence host metabolism and immunity. Currently, bile acid-based therapies including systemic and intestine-restricted FXR agonists, TGR5 agonists, fibroblast growth factor 19 analogue, intestine FXR antagonists, and intestine apical sodium-bile acid transporter (ASBT) inhibitors have been developed as promising treatments for non-alcoholic steatohepatitis (NASH). These pharmacological agents improved metabolic and inflammatory disorders via distinct mechanisms of action that are subjects of extensive research interest. More recently, human and experimental alcoholic liver disease (ALD) has been associated with disrupted bile acid homeostasis. In additional, new findings showed that targeting bile acid metabolism and signaling may be promising therapeutic approaches for treating ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.